logo
Asia-Pacific markets set to open mixed as investors assess U.S.' 15% tariffs on South Korea; await Bank of Japan's rate decision

Asia-Pacific markets set to open mixed as investors assess U.S.' 15% tariffs on South Korea; await Bank of Japan's rate decision

CNBC6 days ago
Good morning from Singapore.
Investors will be keeping a close watch on South Korean markets after U.S. President Donald Trump announced a blanket tariff of 15% on the country's exports to the U.S. Japanese markets will also be watched keenly as the Bank of Japan is expected to stand pat on short-term interest rates at 0.5% at the close of its two-day policy meeting later in the day.
Japan's benchmark Nikkei 225 was set to open higher, with the futures contract in Chicago at 40,855 while its counterpart in Osaka last traded at 40,730, against the index's Wednesday close of 40,654.70.
Futures for Hong Kong's Hang Seng index stood at 24,934, pointing to a weaker open compared with the last close of 25,176.93.
Australia's S&P/ASX 200 was set to start the day lower with futures tied to the benchmark at 8,694, compared with its last close of 8,756.40.
— Amala Balakrishner
The S&P 500 closed lower on Wednesday and gave up its gain from earlier in the session after Federal Reserve Chair Jerome Powell threw some cold water on the prospects of a September rate cut.
The broad market index lost 0.12% to close at 6,362.90. The Nasdaq Composite added 0.15% to 21,129.67, while the Dow Jones Industrial Average fell 171.71 points, or 0.38%, to finish the session at 44,461.28.
— Brian Evans
U.S. Federal Reserve Chair Jerome Powell gestures during a press conference following the issuance of the Federal Open Market Committee's statement on interest rate policy in Washington, D.C., U.S., July 30, 2025.
Jonathan Ernst | Reuters
The Fed can keep the interest rate steady while waiting to see if tariff policy pushes up inflation, Powell said.
"Higher tariffs have begun to show through more clearly to prices of some goods, but their overall effects on economic activity and inflation remain to be seen," Powell said.
Powell said a "reasonable base case" could be that effects to inflation will be "short lived." But he also cautioned that levies could cause inflationary changes that are "more persistent."
"Our obligation is to keep longer term … inflation expectations well anchored and to prevent a one-time increase in the price level from becoming an ongoing inflation problem," Powell said.
"For the time being, we're well positioned to learn more about the likely course of the economy and the evolving balance of risks before adjusting our policy stance," he added. "We see our current policy stance as appropriate to guard against inflation risks."
— Alex Harring
The Fed kept monetary policy unchanged, as was widely expected. However, two central bank officials — Christopher Waller and Michelle Bowman — dissented in the decision, pushing for the Fed to cut the overnight rate by 0.25 percentage point.
This was the first time since 1993 that the Fed's policy decision was met with so much dissent.
— Fred Imbert
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lura Health Announces Strategic Investment and Business Partnership with SCO Group to Advance Intraoral Health Monitoring
Lura Health Announces Strategic Investment and Business Partnership with SCO Group to Advance Intraoral Health Monitoring

Business Wire

timea few seconds ago

  • Business Wire

Lura Health Announces Strategic Investment and Business Partnership with SCO Group to Advance Intraoral Health Monitoring

NEWARK, N.J.--(BUSINESS WIRE)-- Lura Health (UCHU Biosensors, Inc., Head Office: Newark, New Jersey, USA; CEO: Daniel Weinstein), a U.S. health tech company, today announced that it has entered into an investment and business partnership with SCO Group (Head Office: Chiyoda-ku, Tokyo, Japan; Chairman and CEO: Yusuke Tamai), a leading company in Japan's dental technology sector. The goal of the partnership is to deploy Lura Health's intraoral sensor technology into clinical use in Asia and expand its applications globally. Lura Health is developing wearable microsensors that can be worn inside the mouth, either attached to dental appliances or bonded directly to a tooth, to collect real-time biometric data such as pH levels and metabolites in saliva. The company is pioneering a new healthcare model that aims to "visualize whole-body health from within the oral cavity." Background and Purpose of the Partnership Lura Health has created the world's first continuous intraoral salivary monitoring sensor and is targeting medical device approval from the U.S. Food and Drug Administration (FDA) by early 2027. Following regulatory approval, Lura plans to expand its reach into Asian markets, starting with Japan. SCO Group is the operator of "Pay Light X," an integrated dental clinic management platform in Japan that supports appointment booking, diagnosis, payment, and aftercare. By integrating its sensor technology with SCO Group's clinical infrastructure, Lura Health aims to establish a new model for preventive health care in Japan. Key Points of the Partnership Continuous Monitoring with Intraoral Sensors Lura's sensors allow real-time monitoring of oral conditions such as pH and other salivary parameters. These measurements have the potential to supplement or replace conventional lab-based diagnostics in the future. Deployment through SCO Group's Platform By integrating with SCO Group's "Pay Light X," Lura aims to deliver its technology seamlessly to clinicians and patients. Joint pilot projects with Japanese universities and research institutions are expected to begin this fall to generate clinical validation and user feedback. Applications Beyond Dentistry Future use cases for the technology extend into sports performance monitoring, eldercare, and wellness, positioning Lura's sensors as a core tool in comprehensive personal health management. Statement from Daniel Weinstein, CEO of Lura Health "We at Lura Health are honored to announce our investment and business partnership with SCO Group, a leader in digital transformation within the Japanese dental industry. This collaboration represents a major step forward in our mission to enable preventive and user-friendly health monitoring through the diagnostic power of saliva. Our vision aligns deeply with SCO Group's commitment to improving the well-being of individuals through technology. Together, we will combine our sensor innovations with their extensive healthcare network to create tangible societal impact. We look forward to deploying our sensors in real-world clinical settings and co-developing patient-centered products based on live feedback from users in Japan." Partner Statement: Yusuke Tamai, Chairman and CEO of SCO Group "We are very pleased to partner with Lura Health, whose groundbreaking intraoral biosensing technology embodies the future of preventive healthcare. At SCO Group, we have long championed the integration of health technology into daily life, and this partnership allows us to take that mission to the next level. The oral cavity is a gateway to the body's health, yet remains one of the least-monitored areas. By utilizing saliva—a highly accessible source of biological data—we aim to convert invisible health risks into visible insights. Combined with our Pay Light X platform, we intend to build a comprehensive preventive care model that spans diagnosis, treatment, and everyday living." About Lura Health Lura Health is a U.S.-based medical device company developing intraoral microsensors that enable noninvasive, continuous monitoring of health biomarkers via saliva. Led by CEO Daniel Weinstein (Forbes 30 Under 30, Tufts University), the company specializes in microelectronics and biosignal processing and has drawn significant attention in fields such as oral health, diabetes, kidney disease, and therapeutic drug monitoring. LinkedIn:

Trump: Treasury Secretary Scott Bessent doesn't want to be Federal Reserve chair
Trump: Treasury Secretary Scott Bessent doesn't want to be Federal Reserve chair

UPI

timea minute ago

  • UPI

Trump: Treasury Secretary Scott Bessent doesn't want to be Federal Reserve chair

President Donald Trump said Tuesday that Treasury Secretary Scott Bessent said he doesn't want to replace Jerome Powell at the Fed. Photo by Eric Lee/UPI | License Photo Aug. 5 (UPI) -- President Donald Trump said Tuesday that Treasury Secretary Scott Bessent is no longer on the list to replace Federal Reserve Chair Jerome Powell. "Well I love Scott, but he wants to stay where he is," Trump said on CNBC's Squawk Box. "I asked him just last night, 'Is this something you want?' 'Nope I want to stay where I am.'" "I just take him off. He does not want it. He likes being Treasury secretary," Trump said. Powell's term as Fed chair ends in 2026, and Trump has been highly critical of his hesitation to lower interest rates, calling him a "moron" and "too late." Trump is considering his own replacements for the Fed's board of governors amid his criticism of Powell over his stance on interest rates. Others Trump is considering to replace Powell include Kevin Warsh, a financier and bank executive who previously served on the Fed's board of governors, and Kevin Hassett, an economist and the head of the National Economic Council at the White House. "Both Kevins are very good, and there are other people that are very good, too," Trump said, adding that [Adriana] Kugler's resignation "was a pleasant surprise." Kugler, a labor economist, announced Friday that she would step down from the Fed's board of governors this Friday. She plans to return to teaching public policy at Georgetown University in the fall. Another contender for Powell's job is economist and Fed governor Christopher Waller, whom Trump appointed. Trump nominated Powell for the Fed job in 2017, during his first term as president. President Joe Biden reappointed him during his term. Trump alleged Tuesday that Powell told him, "Sir, I'll keep interest rates so low. I'm a low interest rate person." Last week, the Fed kept the interest rate unchanged at 4.25%-4.5%. Waller and governor Michelle Bowman, another Trump appointee, dissented. It was the first time two governors had dissented since 1993.

Should You Buy Kenvue Stock At $22?
Should You Buy Kenvue Stock At $22?

Forbes

timea minute ago

  • Forbes

Should You Buy Kenvue Stock At $22?

Although there has been a recent increase of 21% that aligns with the broader market gains, Kenvue (NYSE: KVUE) offers limited investment appeal at its current valuations. Our thorough analysis encompassing growth, profitability, financial stability, and valuation metrics uncovers fundamental weaknesses that render the stock unattractive for new investors at this time. Kenvue became an independent entity in May 2023 after its spinoff from Johnson & Johnson's consumer health division. As a global consumer health company, Kenvue has shifted from being part of a healthcare conglomerate to functioning as a standalone public company within a competitive consumer products market. That being said, if you are looking for upside with less volatility compared to individual stocks, the Trefis High Quality portfolio serves as an alternative — having outperformed the S&P 500 and delivered returns that exceed 91% since its establishment. Also, see – UNH Stock To $160? Valuation Analysis: Premium Pricing Kenvue is trading at a considerable premium to the overall market across key valuation metrics: While the P/S ratio seems reasonable, the high P/E and P/FCF multiples indicate that investors are paying a significant premium for every dollar of earnings and free cash flow generated. Check out – Kenvue Valuation Ratios – for more information. Growth Performance: Declining Trajectory Kenvue's revenue growth profile shows concerning patterns that do not justify its premium valuation: The ongoing revenue challenges suggest systemic issues in Kenvue's core markets and competitive stance. Profitability Assessment: Mediocre Margins Kenvue's profitability metrics hover around median levels but do not meet market standards: Financial Stability: Adequate but Unremarkable Kenvue sustains satisfactory financial health without notable strengths: Investment Conclusion Kenvue's stock valuation lacks support from its underlying fundamentals. Inconsistent growth and average profitability do not justify the high price relative to the overall market. Although Kenvue enjoys financial stability and operates in the defensive consumer health sector, these favorable attributes are already priced into the current stock value. The combination of high valuation and weak operational fundamentals makes KVUE an unattractive investment opportunity at present levels. Investors looking for exposure to consumer health may be better off waiting for a more favorable entry point or exploring alternatives with stronger growth prospects and more reasonable valuations. See, there is always a notable risk associated with investing in a single or a small number of stocks. Consider TrefisHigh Quality (HQ) Portfolio which, consisting of 30 stocks, has a history of successfully outperforming the S&P 500 over the past 4-year period. Why is that? Collectively, HQ Portfolio stocks have provided superior returns with less risk compared to the benchmark index; a more stable investment experience, as demonstrated in HQ Portfolio performance metrics.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store